SeekingAlpha · Nov 17, 2026
NASDAQ · LEGN
Legend Biotech Corporation
Healthcare · Biotechnology
$16.10
Down-$0.15 (-0.92%)
Updated Nov 20, 2026, 2:38 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.12B
- P/E ratio
- -6.5
- Dividend yield
- 0.00%
- 52-week range
- $15.75 – $37.50
- Volume
- 2.37M
- Avg. volume
- 1.71M
Price performance · LEGN
LEGN price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 19, 2026
LEGN closed at $16.10 after 21 trading sessions, down 14.81% for the selected period.
- Last close
- $16.10
- Period change
- -14.81%
- Period low
- $15.99
- Period high
- $24.29
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 19, 2026 | $16.30 | $16.42 | $15.73 | $16.10 | 2.37M |
| Nov 18, 2026 | $16.12 | $17.057 | $16.03 | $16.25 | 2.15M |
| Nov 17, 2026 | $16.14 | $16.50 | $15.75 | $16.11 | 3.03M |
| Nov 16, 2026 | $17.36 | $17.50 | $15.97 | $15.99 | 2.83M |
| Nov 13, 2026 | $18.46 | $18.61 | $17.385 | $17.50 | 3.03M |
| Nov 12, 2026 | $19.10 | $19.13 | $17.8573 | $18.54 | 4.45M |
| Nov 11, 2026 | $20.67 | $20.73 | $18.87 | $19.54 | 4.42M |
| Nov 10, 2026 | $21.33 | $22.85 | $19.7615 | $20.41 | 6.38M |
| Nov 9, 2026 | $23.80 | $24.42 | $22.88 | $24.29 | 2.04M |
| Nov 6, 2026 | $23.09 | $23.74 | $22.565 | $23.40 | 1.77M |
| Nov 5, 2026 | $22.77 | $23.98 | $22.215 | $22.54 | 3.23M |
| Nov 4, 2026 | $22.44 | $23.72 | $21.70 | $22.77 | 3.16M |
| Nov 3, 2026 | $21.22 | $21.665 | $21.12 | $21.48 | 1.64M |
| Nov 2, 2026 | $21.78 | $21.79 | $20.99 | $21.10 | 1.13M |
| Oct 30, 2026 | $22.12 | $22.42 | $21.34 | $21.63 | 2.19M |
| Oct 29, 2026 | $22.55 | $22.955 | $22.04 | $22.30 | 2.37M |
| Oct 28, 2026 | $21.30 | $22.98 | $20.911 | $22.53 | 2.36M |
| Oct 27, 2026 | $20.39 | $21.665 | $19.9082 | $21.56 | 2.12M |
| Oct 26, 2026 | $19.17 | $21.04 | $19.075 | $20.39 | 2.37M |
| Oct 23, 2026 | $18.87 | $19.29 | $18.44 | $19.27 | 979.58K |
| Oct 22, 2026 | $18.42 | $18.97 | $18.40 | $18.90 | 1.2M |
Latest LEGN news
The latest Smart Investors Daily articles mentioning LEGN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
LEGN research
Overview
Company profile and research snapshot.
Company profile
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $60.67
- Implied upside
- —
- Analysts
- 24
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 16, 2026 | Evercore ISI Group | In-Line | — |
| Nov 11, 2026 | RBC Capital | Outperform | — |
| Nov 11, 2026 | Barclays | Overweight | — |
| Nov 11, 2026 | Morgan Stanley | Overweight | — |
| Nov 11, 2026 | Oppenheimer | Perform | — |
News briefing
No generated briefing is available yet.
Benzinga · Nov 16, 2026
Evercore ISI Group Downgrades Legend Biotech to In-Line, Announces $20 Price Target
Evercore ISI Group analyst Umer Raffat downgrades Legend Biotech (NASDAQ:LEGN) from Outperform to In-Line and announces $20 price target.
Yahoo · Nov 12, 2026
Is Legend Biotech (LEGN) Reasonable After CARVYKTI Sales Growth?
Legend Biotech has had a rough stretch in the market, with a steep multi year share price drop sitting alongside growing interest in its cell therapy franchise. That mix raises a straightforward question for you as an investor: is the current US$19.54 price adequately supported by the company’s sales profile? The stock has fallen 69.3% over the past 3 years, which puts the focus squarely on whether the underlying revenue base can justify even this lower level. Recent updates around CARVYKTI...
Yahoo · Nov 11, 2026
Legend Biotech's Carvykti Positioned to Sustain Growth Into 2027, RBC Capital Markets Says
Legend Biotech's (LEGN) Carvykti therapy for multiple myeloma is positioned to sustain its growth in
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.

